Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up

April 24th 2022, 9:15pm

Transplantation and Cellular Therapy Meetings

The utilization of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphomas produced durable outcomes at a 2 years follow-up.

Belimumab Emerges as Potential Prophylaxis for Chronic GVHD Following Allogenic Transplant

April 24th 2022, 7:58pm

Transplantation and Cellular Therapy Meetings

Belimumab could be a potential treatment used to prevent chronic graft-vs-host-disease in patients undergoing allogeneic hematopoietic transplantation by inhibiting BAFF and limiting the survival of aforeactive B cells.

Axi-cel Demonstrates Long-Term Survival Benefit in Relapsed/Refractory LBCL

April 24th 2022, 3:37pm

Transplantation and Cellular Therapy Meetings

Axicabtagene ciloleucel resulted in a longer overall survival benefit in patients with relapsed or refractory large B-cell lymphoma who did not have event-free survival events at months 12 and 24 vs those who experienced events at these time points.

Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC

April 14th 2022, 5:50pm

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer, and early results have established the pathway as a prime target for drug development.

Neoadjuvant Chemoimmunotherapy Demonstrates Activity in Advanced Ovarian Cancer

April 13th 2022, 7:30pm

AACR Annual Meeting

The addition of durvalumab and tremelimumab to chemotherapy led to encouraging responses and a suitable safety profile as neoadjuvant therapy in patients with advanced ovarian cancer, according to findings from the phase 2 KGOG 3046.

Adebrelimab Plus Chemotherapy Improves Survival Vs Chemotherapy Alone in ES-SCLC

April 13th 2022, 2:59pm

AACR Annual Meeting

The addition of adebrelimab to chemotherapy elicited improved overall survival compared with chemotherapy and placebo in patients with extensive-stage small cell lung cancer.

Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC

April 13th 2022, 2:55pm

AACR Annual Meeting

The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.

Frontline Canakinumab Triplet Misses Mark in Advanced NSCLC, But Shows Benefit in Select Subsets

April 13th 2022, 1:40pm

The addition of canakinumab to frontline pembrolizumab and chemotherapy did not improve survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer. However, signals of activity were seen in patients with a baseline inflammatory biomarker high sensitivity-C-reactive protein.

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

April 13th 2022, 1:24pm

AACR Annual Meeting

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

TTX-030 Plus Budigalimab/mFOLFOX6 Induces Responses in PD-L1–Low Advanced Gastric/GEJ Cancer

April 12th 2022, 11:07pm

The addition of the investigational anti-CD39 antibody TTX-030 to frontline treatment with the PD-L1 inhibitor budigalimab and mFOLFOX6 was determined to be safe and tolerable in patients with locally advanced or metastatic HER2-negative gastroesophageal junction adenocarcinoma.

Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma

April 12th 2022, 8:59pm

AACR Annual Meeting

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.

BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma

April 12th 2022, 8:30pm

AACR Annual Meeting

The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.

Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

April 12th 2022, 7:56pm

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.

MEDI5752 Demonstrates Intriguing Activity in Advanced Solid Tumors

April 12th 2022, 7:55pm

AACR Annual Meeting

MEDI5752 treatment led to a dose-dependent increase in peripheral T-cell proliferation and encouraging antitumor activity in patients with advanced solid tumors.

Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors

April 12th 2022, 7:06pm

AACR Annual Meeting

The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.

Resistance to CAR T-Cell Therapy Predicted by Epigenetic Biomarkers in Pediatric ALL

April 12th 2022, 6:27pm

AACR Annual Meeting

Resistance to CD19-directed CAR T-cell therapy was associated with molecular characteristics identified in pediatric patients with acute lymphoblastic leukemia.

Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC

April 12th 2022, 12:24pm

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma

April 12th 2022, 12:40am

AACR Annual Meeting

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL

April 12th 2022, 12:30am

AACR Annual Meeting

The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.

gLOH-High Status Is Associated With Enhanced Response to Talazoparib in mCRPC

April 11th 2022, 11:56pm

AACR Annual Meeting

High genomic loss of heterozygosity scores may serve as a predictive marker for response to treatment with talazoparib in metastatic castration-resistant prostate cancer.